

New Abstract of the disclosure:

Please amend the application by replacing the Abstract of the Disclosure on page 64 of the translation of the application filed herewith with the attached Abstract of the Disclosure. Please replace the attached Abstract of the Disclosure after the claims and prior to the drawing sheets.

Remarks/Arguments

The Applicants request entry of the foregoing amendments to correct the Sequence Listing filed as part of the specification in the above-identified application. Accompanying this amendment is a substitute Sequence Listing in both computer-readable and paper forms, along with a statement that the disclosures in the computer-readable and paper forms are the same and do not introduce new matter into the disclosure of the application.

As explained in the accompanying statement, SEQ ID NOS: 1-29 of the original and substitute Sequence Listings are identical. Thus, these sequences do not introduce new matter.

SEQ ID NOS: 30 (Mannan-Binding Protein, MBP), 31 (Surfactant protein A, SP-A) and 32 (Surfactant protein D, SP-D) of the substitute Sequence Listing do not introduce new matter into the disclosure of the application. These sequences are fully supported in Figures 2-3 and Figures 5-6 of the specification as originally filed. The substitute Sequence Listing has been prepared with the Patent Office's preferred PatentIn software and is accompanied by the requisite computer-readable copy and statement.

The amendments to the specification merely introduce appropriate cross-references to the sequence listing, consistent with U.S. practice guidelines.

The replacement Abstract of the disclosure is identical to the abstract found on the cover of the published PCT application from which the present application is derived, and it finds support throughout the application.


The applicant intends to file a subsequent preliminary amendment to amend the claims to improve grammar, place the claims in more conventional U.S. form, and minimize the filing fee by eliminating multiple dependancies. The applicants will pay any necessary fees for extra claims at that time.

Also attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402

Date: February 26, 2001



Mark H. Hopkins
Reg. No. 44,775

A3

ABSTRACT

Novel collectin-related molecules expected as exerting antibacterial and antiviral activities, etc. particularly in the human body, namely, a novel collectin gene containing the base sequence represented by SEQ ID NO:1 and novel collectin containing the amino acid sequence represented by SEQ ID NO:2; and a method with the use of the same.

4,414,414

“Version with markings to show changes made.”

In the specification:

Please replace the paragraph beginning at page 1, line 13, with the following amended paragraph:

-- The collectins that have been identified heretofore include mannan-binding protein (MBP, SEQ ID NO: 30), surfactant protein A (SP-A, SEQ ID NO: 31), surfactant protein D (SP-D, SEQ ID NOS: 32), conglutinin and the like. These collectins are known to be constituted from basic structures (Fig. 1) comprising unique regions of: (1) Ca^{2+} -dependent carbohydrate recognition domain (CRD), and (2) collagen-like region [Malhortra *et al.*, *Eur. J. Immunol.* Vol. 22, 1437-1445, 1992], and a subunit may be formed from the three basic structures through making a triple helix in the collagen-like region, besides, such subunits may form an oligomer, e.g. trimer, tetramer and hexamer.--

Please replace the paragraphs at page 3, lines 16-27, with the following amended paragraphs:

-- Figure 2 shows the alignment of the preceding half portions of amino acid sequences (SEQ ID NOS: 30-32) of three collectins reported heretofore;

Figure 3 shows the alignment of the latter half portions of the amino acid sequences (SEQ ID NOS: 30-32) in Figure 2;

Figure 4 shows each of the primers used for sequencing the novel collectin of the present invention, and the nucleotide sequences which were read out from the sequencer (b); and an ORF of the obtained novel collectin (a);

Figure 5 shows the alignment of the preceding half portions of amino acid sequences (SEQ ID NOS: 30-32) of the three collectins reported heretofore and the novel collectin of the present invention (SEQ ID NO: 2, residues 206-547);

Figure 6 shows the alignment of the latter half portions of the amino acid sequences (SEQ ID NOS: 2 and 30-32) in Figure 5;--